Interstitial Lung Abnormalities in Renal Transplant Recipients (LCRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01017757
Recruitment Status : Unknown
Verified November 2009 by University of Parma.
Recruitment status was:  Active, not recruiting
First Posted : November 23, 2009
Last Update Posted : November 23, 2009
Information provided by:
University of Parma

Brief Summary:
Immunosuppressive drugs such as tacrolimus, cyclosporine, mycophenolate mofetil, sirolimus and everolimus may have toxic pulmonary effects, particularly interstitial alterations. The aim of the present study is to explore the presence of subclinical interstitial lung abnormalities in stable renal transplant recipients taking the different immunosuppressive drugs used as maintenance therapy for renal transplantation.

Condition or disease Intervention/treatment
Renal Transplantation Kidney-pancreas Transplantation Procedure: High-resolution CT scanning

Detailed Description:

Prospective, cross-sectional study examining the high-resolution CT scans obtained in 63 stable renal transplant recipients taking immunosuppressive treatment for at least 24 months. The findings in patients taking the newer immunosuppressive drugs (mycophenolic acid, sirolimus and everolimus) are compared with those of the patients treated in the traditional way (cyclosporine, tacrolimus, azathioprine). All patients undergo high-resolution CT scanning.

Eligibility criteria: recipients of kidney or kidney-pancreas transplant, on immunosuppressive therapy for at least 24 months, with stable renal function and absence of any overt lung disease or lung alterations induced by other drugs, systemic diseases or occupational exposure to fibrogenic agents.

Study Type : Observational
Actual Enrollment : 63 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cross-sectional Analysis of Subclinical Interstitial Lung Abnormalities in Stable Renal Transplant Recipients by High-resolution CT Scan
Study Start Date : June 2007
Actual Primary Completion Date : October 2007
Estimated Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Renal transplant patients Procedure: High-resolution CT scanning
High-resolution CT scanning

Primary Outcome Measures :
  1. Subclinical lung alterations as assessed by high-resolution CT scanning [ Time Frame: CT is performed at study entry and, if abnormalities are found, it is repeated at 3-6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 82 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Kidney or kidney-pancreas recipients, on immunosuppressive therapy for at least 24 months

Inclusion Criteria:

  • Renal transplant patients with stable renal function taking immunosuppressive therapy for at least 24 months and providing written informed consent to participate to the study

Exclusion Criteria:

  • Overt lung disorders, lung toxicity due to other drugs or occupational exposure to lung-toxic agents
  • Systemic connective tissue disorders or systemic vasculitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01017757

Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital
Parma, Italy, 43100
Sponsors and Collaborators
University of Parma
Principal Investigator: Carlo Buzio, MD University of Parma

Responsible Party: Carlo Buzio, University of Parma Identifier: NCT01017757     History of Changes
Other Study ID Numbers: LungCtRenalTx
First Posted: November 23, 2009    Key Record Dates
Last Update Posted: November 23, 2009
Last Verified: November 2009

Keywords provided by University of Parma:
Interstitial lung disease
Immunosuppressive therapy
Renal transplant